Long-acting β2-agonists in management of childhood asthma: A critical review of the literature

Pediatric Pulmonology

Volumn 29, Issue 3, 2000, Pages 221-234

  Bisgaard, Hans ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Asthma; Children; Formoterol; Long acting 2 agonists; Randomized controlled trials; Salmeterol; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; FORMOTEROL FUMARATE; LONG ACTING DRUG; METHACHOLINE; OXIS TURBUHALER; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE; UNCLASSIFIED DRUG;

ASTHMA; BRONCHODILATATION; BRONCHOSPASM; BRONCHUS REACTIVITY; CHILD; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG INTERMITTENT THERAPY; DRUG TOLERANCE; EXERCISE; HEADACHE; HEART PALPITATION; HUMAN; LUNG FUNCTION; METERED DOSE INHALER; POWDER INHALER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREMOR;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANTI-INFLAMMATORY AGENTS; ASTHMA; ASTHMA, EXERCISE-INDUCED; BRONCHI; BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR AGENTS; CHILD; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG TOLERANCE; ETHANOLAMINES; GLUCOCORTICOIDS; HUMANS; LUNG; RANDOMIZED CONTROLLED TRIALS; STATUS ASTHMATICUS;

EID: 0034008825     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(200003)29:3<221::AID-PPUL11>3.0.CO;2-P     Document Type: Review

References (73)

1. 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 1989;84:891-895.
2. 2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma. Pediatr Pulmonol 1989;7:89-93.
3. Graff-Lonnevig V, Browaldh L. Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol. Clin Exp Allergy 1990;20:429-432.
4. Foucard T, Lönnerholm G. A study with cumulative doses of formoterol and salbutamol in children with asthma. Eur Respir J 1991;4:1174-1177.
5. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992;89:1176-1182.
6. Boner AL, Spezia E, Piovesan P, Chiocca A, Maiocchi G. Inhaled formoterol in the prevention of exercise induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med 1994;149:935-939.
7. Daubjerg P, Nielsen, KG, Skov M, Bisgaard H. Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise induced asthma in children. Acta Paediatr 1996;85:684-687.
8. Nielsen KG, Skov M, Klug B, Ifversen M, Bisgaard H. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. Eur Respir J 1997;10:2105-2109.
9. Simons FER, Soni NR, Watson WTA, Becker AB. Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma. J Allergy Clin Immunol 1992;90:840-846.
10. Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992;67:1014-1017.
11. Verberne AAPH, Hop WCJ, Bos AB, Kerrebijn KF. Effect of a single dose of inhaled salmeterol on baseline airway calibre and methacholine-induced airway obstruction in asthmatic children. J Allergy Clin Immunol 1993;91:127-134.
12. Barbato A, Cracco A, Tomena F, Novelle A. The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children. Allergy 1995;50:506-510.
13. Carlsen KH, Roksund O, Olsholt K, Nja F, Leegaard J, Bratten G. Overnight protection by inhaled salmeterol on exercise-induced asthma in children. Eur Respir J 1995;8:1852-1855.
14. de Benedictis FM, Tuteri G, Pazzelli P, Niccoli A, Mezzetti D, Vaccaro R. Salmeterol in exercise-induced bronchoconstriction in asthmatic children: comparison of two doses. Eur Respir J 1996;9:2099-2103.
15. Weinstein S, Chervinsky P, Pollard SJ, Bronsky EA, Nathan RA, Prenner B, Howland WC, Stahl E, Liddle R. A one-week dose-ranging study of inhaled salmeterol in children with asthma. J Asthma 1997;34:43-52.
16. Nielsen KG, Auk IL, Bojsen K, Ifversen M, Klug B, Bisgaard H. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur Respir J 1998;11:350-354.
17. Gustafsson PM, Von Verg A, Jenkins MM. Salmeterol 50 μg twice daily in the treatment of mild-to-moderate asthma in childhood - a comparison of two inhalation devices. Eur J Clin Res 1994;5:63-73.
18. Meijer GG, Postma DS, Mulder PGH, van Aalderen WM. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Am J Respir Crit Care Med 1995;152:1887-1892.
19. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995;75:423-428.
20. Langton Hewer S, Hobbs J, French D, Lenney W. Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma. Respir Med 1995;89:435-440.
21. Lenney W, Pedersen S, Boner AL, Ebbutt A, Jenkins MM. Efficacy and safety of salmeterol in childhood asthma. Eur J Pediatr 1995;154:983-990.
22. Verberne AAPH, Hop WC, Creyghton FB, van Rooij RW, van den Berg M, de Jongste JC, Kerrebijn KF. Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. J Allergy Clin Immunol 1996;97:938-946.
23. Verberne AAPH, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997;156:688-695.
24. Simons FER. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med 1997;337:1659-1665.
25. Simons FER, Gerstner TV, Chang MS. Tolerance to the broncho-protective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99:655-659.
26. Weinstein SF, Pearlman DS, Bronsky EA, Byrne A, Arledge T, Liddle R, Stahl E. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. Ann Allergy Asthma Immunol 1998;81:51-58.
27. Zarkovic J, Götz MH, Holgate ST, Taak NK. Effect of long-term regular salmeterol treatment in children with moderate asthma. Clin Drug Invest 1998;15;169-175.
28. Von Berg A, De Blic J, La Rosa M, Kaad PH, Moorat A. A comparison of regular salmeterol versus "as required" salbutamol therapy in asthmatic children. Respir Med 1998;92:292-299.
29. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998;158:213-219.
30. Fuglsang G, Vikre-Jorgensen J, Agertoft L, Pedersen S. Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. Pediatr Pulmonol 1998;25:314-321.
31. Johnson M, Butchers PR, Coleman RA, Nials AT, Strong P, Sumner MJ, Vardey CJ, Whelan CJ. The pharmacology of salmeterol. Life Sci 1993;52:2131-2143.
32. 2-adrenoceptor agonist bronchodilator. Life Sci 1993;52:2145-2160.
33. Jeppsson AB, Löfdahl CG, Waldeck B, Widmark E. On the predictive value of experiments in vitro in the evaluation of the effect duration of bronchodilator drugs for local administration. Pulmonary Pharmacol 1989;2:81-85.
34. Jeppsson AB, Roos C, Waldeck B, Widmark E. Pharmacodynamic and pharmacokinetic aspects of the transport of bronchodilator drugs through the tracheal epithelium of the guinea-pig. Pharmacol Toxicol 1989;64:58-63.
35. 2-adrenoceptor agonists long-acting? Eur Respir J 1994;7:569-578.
36. 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol 1994;113:687-692.
37. Buxton BF, Jones CR, Molenaar P, Summers RJ. Characterization and autoradiographic localization of β-adrenoceptor subtypes in human cardiac tissues. Br J Pharmacol 1987;92:299-310.
38. 2-agonist. Clin Pharmacol Ther 1986;40:108-115.
39. Bisgaard H. Delivery of inhaled medication to children. J Asthma 1997;34:443-468.
40. Bartow RA, Brogden RN. Formoterol. An update on its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998;55:303-322.
41. Adkins JC, McTavish D. Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs 1997;54:331-354.
42. Rabe KF, Jörres R, Nowak D. Comparison of the effects of salmeterol and formeterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993;147:1436-1441.
43. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998;133:424-428.
44. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg BC, Reiss TF. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-152.
45. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroids in asthma patients with symptoms on existing inhaled corticosteroids. Lancet 1994;344:219-224.
46. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-1488.
47. Pauwels RA, Löfdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-1411.
48. 2-agonist in asthma. N Engl J Med 1992;327:1204-1208.
49. Cockcroft DW, McParland CP, Britto SA, Swysdim VA, Pindherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993;342:833-837.
50. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995;96:44-49.
51. Sears MR. Epidemiological trends in asthma. Can Respir J 1996;3:261-268.
52. 2-agonist treatment in bronchial asthma. Lancet 1990;336:1391-1396.
53. Cockcroft DW, Swystun VA, Bhagat R, Kalra S. Salmeterol and airway response to allergen. Can Respir J 1997;4:37-40.
54. Giannini D, Carletti A, Dente FL, Bacci E, Di Franco A, Vagaggini B, Paggiaro PL. Tolerance to the protective effect of salmeterol on allergen challenge. Chest 1996;110:1452-1457.
55. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-1203.
56. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363-368.
57. Bhagat R, Kalra S, Swystun VA, Cockroft DW. Rapid onset of tolerance to the broncho-protective effect of salmeterol. Chest 1995;108:1235-1239.
58. Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996;51:1100-1104.
59. Kalra S, Swystun VA, Bhagat R, Cockroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the broncho-protective effect of salmeterol. Chest 1996;109:953-956.
60. 2-agonist. Am J Respir Crit Care Med 1996;154:1603-1607.
61. Lipworth BJ, Tan KS, Devlin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998;104:431-438.
62. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995;346:201-206.
63. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995;152:838-860.
64. Tan KS, Grove A, McLean A, Gnosspeliüs Y, Hall IP, Lipworth BJ. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997;156:28-35.
65. Boulet LP, Cartier A, Milot J, Cote J, Malo JL, Laviolette M. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur Respir J 1998;11:1091-1097.
66. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER. Effect of long-term salmeterol treatment on exercise induced asthma. N Engl J Med 1998;339:141-146.
67. Turner MO, Johnston PR, Pizzichini E, Pizzichini MM, Hussack PA, Hargreave FE. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can Respir J 1998;5:261-268.
68. Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effects of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994;150:1006-1011.
69. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-930.
70. Tötterman KJ, Huhti L, Sutinen E, Backman R, Pietinalho A, Falck M, Larsson P, Selroos O. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J 1998;12:573-579.
71. British Thoracic Society. British Thoracic Society guidelines on the management of asthma. Thorax [Suppl] 1997;52:1-21.
72. Global Initiative for Asthma. Global strategy for asthma management and prevention. Publication Number 95-3659. Washington: National Heart, Lung and Blood Institute, National Institutes of Health; 1995.
73. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995;95:29-33.